The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Krukov A.I.

Sverzhevsky Moscow Scientific and Practical Othorhinolaryngology Center, Moscow

Kunel’skaya N.L.

N.I. Pirogov Russian National Research Medical University, Moscow, Russia, 117997;
L.I. Sverzhevsky Moscow Research and Practical Centre of Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152

Shershunova E.A.

The Institute for Electrophysics and Electric Power of the Russian Academy of Sciences, Saint-Petersburg, Russia, 191186

Rebrov I.E.

The Institute for Electrophysics and Electric Power of the Russian Academy of Sciences, Saint-Petersburg, Russia, 191186

Yamshchikov V.A.

The Institute for Electrophysics and Electric Power of the Russian Academy of Sciences, Saint-Petersburg, Russia, 191186

Garov E.V.

Moskovskiĭ nauchno-prakticheskiĭ tsentr otorinolaringologii Departamenta zdravookhraneniia Moskvy

Tsarapkin G.Yu.

Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russia

Mishchenko V.V.

L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152

Topical drug administration to the inner ear. Modern state of the problem and development perspectives

Authors:

Krukov A.I., Kunel’skaya N.L., Shershunova E.A., Rebrov I.E., Yamshchikov V.A., Garov E.V., Tsarapkin G.Yu., Mishchenko V.V.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2019;84(5): 6‑14

DOI: 10.17116/otorino2019840516

Read: 9009 times

Download PDF (RU)
Contact the author
Table of contents

TOPICAL DRUG ADMINISTRATION TO THE INNER EAR. MODERN STATE OF THE PROBLEM AND DEVELOPMENT PERSPECTIVES
TOPICAL DRUG ADMINISTRATION TO THE INNER EAR. MODERN STATE OF THE PROBLEM AND DEVELOPMENT PERSPECTIVES

To cite this article:

Krukov AI, Kunel’skaya NL, Shershunova EA, et al. . Topical drug administration to the inner ear. Modern state of the problem and development perspectives. Russian Bulletin of Otorhinolaryngology. 2019;84(5):6‑14. (In Russ.)
https://doi.org/10.17116/otorino2019840516

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Meniere’s disease and vestibular migraine: differential diagnostics and treatment. Russian Bulletin of Otorhinolaryngology. 2025;(1):57-63
Diagnosis of laby­rinth hydrops in patients on different stages of Meniere’s disease. Russian Bulletin of Otorhinolaryngology. 2025;(3):24-29
The effe­ctiveness of adequate correction of audi­tory function on cognitive function. Russian Bulletin of Otorhinolaryngology. 2025;(4):105-111
Endaural phonoelectrophoresis with dexa­methasone in the treatment of Meniere’s disease. Russian Bulletin of Otorhinolaryngology. 2025;(6):19-23
Abstract:

The work assessed modern methods of drug delivery through biological barriers to the lesion, in particular, through the most studied — skin. The main advantages and disadvantages of the existing methods for the topical administration of drugs into the inner ear — intra-imperial and intra-labyrinth delivery are analyzed. A brief review of medicinal substances for topical administration to the inner ear, both widely used (for example, aminoglycosides, steroid drugs) and undergoing clinical trials, is given. An assessment is made of the prospects for the use of transmembrane drug delivery to the inner ear using an electric field, which has a combined electro-creative and iontophoretic effect.

Keywords:

electroporation
inner ear
Meniere’s disease
translabirint drug delivery
neurosensory hearing loss
cochleovestibular disorders
phonoelectrophoresis

Authors:

Krukov A.I.

Sverzhevsky Moscow Scientific and Practical Othorhinolaryngology Center, Moscow

Kunel’skaya N.L.

N.I. Pirogov Russian National Research Medical University, Moscow, Russia, 117997;
L.I. Sverzhevsky Moscow Research and Practical Centre of Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152

Shershunova E.A.

The Institute for Electrophysics and Electric Power of the Russian Academy of Sciences, Saint-Petersburg, Russia, 191186

Rebrov I.E.

The Institute for Electrophysics and Electric Power of the Russian Academy of Sciences, Saint-Petersburg, Russia, 191186

Yamshchikov V.A.

The Institute for Electrophysics and Electric Power of the Russian Academy of Sciences, Saint-Petersburg, Russia, 191186

Garov E.V.

Moskovskiĭ nauchno-prakticheskiĭ tsentr otorinolaringologii Departamenta zdravookhraneniia Moskvy

Tsarapkin G.Yu.

Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russia

Mishchenko V.V.

L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152

Close metadata

References:

  1. Kunel’skaya NL. Reabilitatsiya patsiyentov s razlichnymi formami neyrosensornoy tugoukhosti. Russian Medical Journal. 2011;19(24):1478-1482. (In Russ.)
  2. Sosnov AV, Ivanov RV, Balakin KV, Shobolov DL, Fedotov YuA, Kalmykov YuM. Development of drug delivery systems using micro and nanoparticles. Good Clinical Practice. 2008;2:4-12. (In Russ.)
  3. Prausnitz MR. A practical assessment of transdermal drug delivery by skin electroporation. Advanced Drug Delivery Reviews. 1999;35(1):61-76.
  4. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nature Reviews Drug Discovery. 2004;3(2):115. https://doi.org/10.1038/nrd1304
  5. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. European Journal of Pharmaceutical Sciences. 2001;14(2):101-114.
  6. Das Kurmi B, Tekchandani P, Paliwal R, Rai Paliwal S. Transdermal drug delivery: Opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers. Current Drug Metabolism. 2017;18(5):481-495. https://doi.org/10.2174/1389200218666170222150555
  7. Schaefer H, Redelmeier TE. In: Skin Barrier. Principles of Percutaneous Absorption. 1996; Karger, Basel. pp. 235-237.
  8. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharmaceutical Science & Technology Today. 2000;3(9):318-326.
  9. Fick A. Ueber diffusion. An Phys. 1855;59.
  10. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: an overview. Skin Pharmacology and Physiology. 2007;20(6):272-282.
  11. Samad A, Sultana Y, Aqil, M. Liposomal drug delivery systems: an update review. Current Drug Delivery. 2007;4(4):297-305. https://doi.org/10.2174/156720107782151269
  12. Kumar MNVR. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci. 2000;3(2):234-258.
  13. Kost J, Pliquett U, Mitragotri SS, Langer RS, Weaver JCUS. Patent No. Washington, DC: U.S. Patent and Trademark Office. 2000;6,041,253.
  14. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nature Reviews Drug Discovery. 2005;4(3):255. https://doi.org/10.1038/nrd1662
  15. Kryukov AI. Development of pharmacophysical effects on the auditory receptor in neurosensory hearing loss (clinical and experimental study). M. 2007. (In Russ.)
  16. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. Journal of Pharmaceutical Sciences. 1998;87(8):922-925. https://doi.org/10.29161/PT.v6.i1.2018.7
  17. Medi BM, Layek B, Singh J. Electroporation for Dermal and Transdermal Drug Delivery. In: Percutaneous Penetration Enhancers Physical Methods in Penetration Enhancement. Springer, Berlin, Heidelberg. 2017;105-122.
  18. Green P. Iontophoretic delivery of peptide drugs. Journal of Controlled Release. 1996;41(1-2):33-48.
  19. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proceedings of the National Academy of Sciences. 1993;90(22):10504-10508.
  20. Palchun VT, Kunelskaya NL, Kryukov AI. Treatment of cochlear neuritis of vascular genesis by methods of endaural phonophoresis and phonoelectrophoresis. Bulletin of Otorhinolaryngology. 1989;3:46-48. (In Russ.)
  21. Bhatia KS, Singh J. Mechanism of transport enhancement of LHRH through porcine epidermis by terpenes and iontophoresis: permeability and lipid extraction studies. Pharm Res. 1998;15:1857-1862.
  22. Le L, Kost J, Mitragotri S. Combined effect of low frequency ultrasound and iontophoresis: application for transdermal heparin delivery. Pharm Res. 2000;17:1151-1154.
  23. Prausnitz MR. Advanced Drug Delivery Reviews. 1999;35:61-76.
  24. Walker RB, Smith EW. The role of percutaneous penetration enhancers. Advanced drug delivery Reviews. 1996;18(3):295-301.
  25. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. Journal of Controlled Release. 1994;30(1):1-15.
  26. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science. 1995;269(5225):850-853.
  27. Prausnitz MR, Lee CS, Liu CH, Pang JC, Singh TP, Langer R, Weaver JC. Transdermal transport efficiency during skin electroporation and iontophoresis. Journal of Controlled Release. 1996;38(2-3):205-217.
  28. Sage BH. Iontophoresis. In: Smith E.W., Maibach H.I. (Eds.), Percutaneous Penetration Enhancers. CRC Press, Boca Raton. 1995;351-368.
  29. Chernomordik LV, Sukharev SI, Popov SV, Pastushenko VF, Sokirko AV, Abidor IG, Chizmadzhev YA. The electrical breakdown of cell and lipid membranes: the similarity of phenomenologies. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1987;902(3):360-373. https://doi.org/10.1016/0005-2736%2887%2990204-5
  30. Dimitrov DS, Sowers AE. Membrane electroporaton-fast molecular exchange by electroosmosis. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1990;1022(3):381-392.
  31. Weaver JC. Electroporation of cells and tissues. IEEE Transactions on Plasma Science. 2000;28(1):24-33.
  32. Fromm ME, Taylor LP, Walbot V. Stable transformation of maize after gene transfer by electroporation. Nature. 1986;319(6056):791.
  33. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes. 1993;1154(1):51-63.
  34. Gift EA, Weaver JC. Observation of extremely heterogeneous electroporative molecular uptake by Saccharomyces cerevisiae which changes with electric field pulse amplitude. Biochimica et Biophysica Acta (BBA). Biomembranes. 1995;1234(1):52-62.
  35. Weaver JC, Vaughan TE, Chizmadzhev Y. Theory of electrical creation of aqueous pathways across skin transport barriers. Advanced Drug Delivery Reviews. 1999;35(1):21-39.
  36. Muller KJ, Sukhorukov VL, Zimmermann U. Reversible electropermeabilization of mammalian cells by high-intensity, ultra-short pulses of submicrosecond duration. The Journal of Membrane Biology. 2001;184(2):161-170.
  37. Ersner MS, Spiegel EA, Alexander MH. Transtympanic injection of anesthetics for the treatment of Meniere’s Syndrome. AMA Archives of Otolaryngology. 1951;54(1):43-52.
  38. Schuknecht HF. Ablation therapy for the relief of Meniere’s disease. The Laryngoscope. 1956;66(7):859-859.
  39. Barrs DM. Intratympanic corticosteroids for Meniere’s disease and vertigo. Otolaryngologic Clinics of North America. 2004;37(5):955-72.
  40. Mikulec AA, Plontke SK, Hartsock JJ, Salt AN. Entry of substances into perilymph through the bone of the otic capsule following intratympanic applicatons in guinea pigs: Implications for local drug delivery in humans. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2009;30(2):131.
  41. Salt AN, Plontke SK. Principles of local drug delivery to the inner ear. Audiology and Neurotology. 2009;14(6):350-360. https://doi.org/10.1159/000241892
  42. Saijo S, Kimura RS. Distribution of HRP in the inner ear after injection into the middle ear cavity. Acta Otolaryngological. 1984;97(5-6):593-610.
  43. Goycoolea MV, Lundman L. Round window membrane. Structure function and permeability: a review. Microscopy Research and Technique. 1997;36(3):201-211.
  44. Hoft J. The permeability of the round window membrane and its changes by pantocaine (tetracaine). Archiv fur klinische und experimentelle. Ohren Nasen und Kehlkopfheilkunde. 1969;193(2):128.
  45. Selivanova O, Maurer J, Ecke U, Mann WJ. The effects of Streptolysin-O and sodium hyaluronate on the permeability of the round window membrane in guinea pigs — an electrophysiologic study. Laryngo Rhino Otologie. 2003;82(4):235-239. https://doi.org/10.1055/s-2003-38937
  46. Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Connelly PE, Huang E, Baredes S. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngology Head and Neck Surgery. 2000;122(4):521-528. https://doi.org/10.1067/mhn.2000.102578
  47. Mikulec AA, Hartsock JJ, Salt AN. Permeability of the round window membrane is influenced by the composition of applied drug solutions and by common surgical procedures. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2008;29(7):1020. https://doi.org/10.1097%2FMAO.0b013e31818658ea
  48. Li W, Hartsock JJ, Dai C, Salt AN. Permeation Enhancers for Intratympanically-applied Drugs Studied Using Fluorescent Dexamethasone as a Marker. Otology & Neurotology. 2018;39(5):639-647. https://doi.org/10.1097%2FMAO.0000000000001786
  49. Alexander TH, Harris JP, Nguyen OT, Vorasubin N. Dose effect of intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss: 24 mg/mL is superior to 10 mg/mL. Otology & Neurotology. 2015;36(8):1321-1327. https://doi.org/10.1097/MAO.0000000000000834
  50. Salt AN. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2008;29(3):401. https://doi.org/10.1097%2FMAO.0b013e318161aaae
  51. Beyea JA, Instrum RS, Agrawal SK, Parnes LS. Intratympanic Dexamethasone in the Treatment of Meniere’s Disease: A Comparison of Two Techniques. Otology & Neurotology. 2017;38(6):173-178. https://doi.org/10.1097/MAO.0000000000001437
  52. Salt AN, Gill RM, Plontke SK. Dependence of hearing changes on the dose of intratympanically applied gentamicin: a meta-analysis using mathematical simulations of clinical drug delivery protocols. The Laryngoscope. 2008;118(10):1793-1800. https://doi.org/10.1097%2FMLG.0b013e31817d01cd
  53. Bowe SN, Jacob A. Round window perfusion dynamics: implications for intracochlear therapy. Curr Opin Otolaryngol Head Neck Surg. 2010;18(5):377-385. https://doi.org/10.1097/MOO.0b013e32833d30f0
  54. Ayoob A, Borenstein JT. The role of intracochlear drug delivery devices in the management of inner ear disease. Expert Opin. Drug Deliv. 2014;12(3):1-15. https://doi.org/10.1517/17425247.2015.974548
  55. Hoffer ME, Kopke RD, Wiesskopf P, et al. Microdose gentamicin administration via the round window microcatheter: result in patients with Meniere’s disease. Ann NY Acad Sci. 2001;942:46-51. https://doi.org/10.1111/j.1749-6632.2001.tb03734.x
  56. Lefebvre PP, Staecker H. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol. 2002;122:698-702.
  57. Arnold W, Senn P, Hennig M, Michaelis C, Deingruber K, Scheler R, Lamm K. Novel slow-and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs. Audiology and Neurotology. 2005;10(1):53-63. https://doi.org/10.1159/000082575
  58. Plontke SK, Mynatt R, Gill RM, Borgmann S, Salt AN. Concentration gradient along the scala tympani after local application of gentamicin to the round window membrane. The Laryngoscope. 2007;117(7):1191-1198. https://doi.org/10.1097/MLG.0b013e318058a06b
  59. Salt AN, Hale SA, Plonkte SK. Perilymph sampling from the cochlear apex: a reliable method to obtain higher purity perilymph samples from scala tympani. Journal of Neuroscience Methods. 2006:153(1):121-129. https://doi.org/10.1016/j.jneumeth.2005.10.008
  60. Plontke SK, Gotze G, Rahne T, Liebau A. Intracochlear drug delivery in combination with cochlear implants. Hno. 2017;65(1):19-28. https://doi.org/10.1007/s00106-016-0285-9
  61. Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otology & Neurotology. 2007;28(8):1124-1130. https://doi.org/10.1097/MAO.0b013e31815aee21
  62. Kiefer J, Gstoettner W, Baumgartner W, Pok SM, Tillein J, Ye O, Von Ilberg C. Conservation of low- frequency hearing in cochlear implantation. Acta oto-laryngologica. 2004;124(3):272-280.
  63. Garnham C, Reetz G, Jolly C, Miller J, Salt A, Beal F. Drug delivery to the cochlea after implantation: consideration of the risk factors. Cochlear Implants International. 2005;6(suppl 1):12-14.
  64. Schuknecht HF. Ablation therapy for the relief of Meniere’s disease. Laryngoscope. 1956;66(7):859-870.
  65. Carey J. Intratympanic gentamicin for the treatment of Meniere’s disease and other forms of peripheral vertigo. Otolaryngologic Clinics of North America. 2004;37(5):1075-1090. https://doi.org/10.1016/j.otc.2004.06.002
  66. Staecker H, Rodgers B. Development in delivery of medications for inner ear disease. Expert Opin Drug Deliv. 2013;10(5). https://doi.org/10.1517/17425247.2013.766167
  67. Lawrence R, Thevasagayam R. Controversies in the management of sudden sensorineural hearing loss: an evidence based review. Clin Otolar. 2015;40(3):176-182. https://doi.org/10.1111/coa.12363
  68. Wei BP, Stathopoulos D, O’Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD003998.pub3
  69. Staecker H, Jokovic G, Karpishchenko S, et al. Efficacy and safety of AM-111 in the treatment of acute unilateral sudden deafness — a double-blind, randomized, placebo-controlled Phase 3 study. Otol Neurotol. 2019. Epub ahead of print. https://doi.org/10.1097/MAO.0000000000002229
  70. Campbell K, Claussen A, Meech R, Verhulst S, Fox D, Hughes L. D-methionine (D-met) significantly rescues noise-induced hearing loss: timing studies. Hear Res. 2011;282(1-2):138-144. https://doi.org/10.1016/j.heares.2011.08.003
  71. Alagic Z, Goiny M, Canlon B. Protection against acoustic trauma by direct application of D-metionine to the inner ear. Acta Otolaryngol. 2011;131(8):802-808. https://doi.org/10.3109/00016489.2011.564652
  72. Ekborn A, Laurell G, Johnstrom P. D-Methionine and cisplatin ototoxity in the guinea pig: D-methionine influences cisplatin pharmacokinetics. Hear Res. 2002;165(1-2):53-61.
  73. Campbell KC, Martin SM, Meech RP, Hargrove TL, Verhulst SJ, Fox DJ. D-methionine (D-met) significantly reduces kanamycin-induced ototoxicity in pigmented guinea pigs. Int J Audiol. 2016;55(5):273-278. https://doi.org/10.3109/14992027.2016.1143980
  74. Wimmer C, Mees K, Stumpf P, Welsch U, Reichel O, Suckfüll M. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004;25(1):33-40.
  75. Rewerska A, Pawelczyk M, Raikowska E, et al. Evaluating D-metionine dose to attenuate oxidative stress-mediated hearing loss following overexposure to noise. Eur Arch Otorhinolaryngol. 2013;270(4):1513-1520. https://doi.org/10.1007%2Fs00405-012-2265-3
  76. Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol. 2004;25(6):910-915.
  77. Riga MG, Chelis L, Kakolyris S, Papadopoulos S, Stathakidou S, Chamalidou E, Xenidis N, Amarantidis K, Dimopoulos P, Danielides V. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasi. Am J Clin Oncol. 2013;36(1):1-6. https://doi.org/10.1097/COC.0b013e31822e006dble method with promising efficacy
  78. Sarafraz Z, Ahmadi A, Daneshi A. Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial. Int Tinnitus J. 2018;22(1):40-45. https://doi.org/10.5935/0946-5448.20180007
  79. Angeli SI, Abi-Hachem RN, Vivero RJ, Telischi FT, Machado JJ. L-N-Acetylcysteine treatment is associated with improved hearing outcome in sudden idiopathic sensorineural hearing loss. Acta Otolaryngol. 2012;132(4):369-376. https://doi.org/10.3109/00016489.2011.647359
  80. Inaoka T, Nakagawa T, Kikkawa YS, Tabata Y, Ono K, Yoshida M, et al. Local application of hepatocyte growth factor using gelatin hydrogels attenuates noise-induced hearing loss in guinea pigs. Acta Otolaryngol. 2009;129(4):453-457. https://doi.org/10.1002/lary.20602
  81. Iwai K, Nakagawa T, Endo T, Matsuoka Y, Kita T, Kim TS, et al. Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel. Laryngoscope. 2006;116(4):529-533.
  82. Fijiwara T, Hato N, Nakagawa T, Tabata Y, Yoshida T, Komobuchi H. et al. Insulin-like growth factor 1 treatment via hydrogels rescues cochlear hair cells from ischemic injury. Neuroreport. 2008;19(16):1585-1588. https://doi.org/10.1097/WNR.0b013e328311ca4b
  83. Demir MG, Altintoprak N, Aydin S, Kosemihal E, Basak K. Effect of transtympanic injection of melatonin of cisplatin-induced ototoxity. J Int Adv Otol. 2015;11(3):202-206. https://doi.org/10.5152/iao.2015.1094
  84. Suzuki J, Corfas G, Liberman MC. Round-window delivery of neurotrophin 3 regenerates cochlear synapses after acoustic overexposure. Sci Rep. 2016;25(6):24-27. https://doi.org/10.1038/srep24907
  85. Prausnitz MR, Lee CS, Liu CH, Pang JC, Singh TP, Langer R, Weaver, JC. Transdermal transport efficiency during skin electroporation and iontophoresis. Journal of Controlled Release. 1996;38(2-3):205-217.
  86. Lombry C, Dujardin N, Preat V. Transdermal delivery of macromolecules using skin electroporation. Pharmaceutical Research. 2000;17(1):32-37.
  87. Hofmann GA, Crandell LJ. U.S. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells US5507724A. Patent No. 5,507,724. Washington, DC: U.S. Patent and Trademark Office; 1996.
  88. Hofmann GA, Crandell LJ. U.S. Electroporation and iontophoresis catheter with porous balloon US5704908A. Patent No. 5,704,908. Washington, DC: U.S. Patent and Trademark Office; 1998.
  89. Napotnik TB, Rebersek M, Kotnik T, Lebrasseur E, Cabodevila G, Miklavcic D. Electropermeabilization of endocytotic vesicles in B16 F1 mouse melanoma cells. Medical & Biological Engineering & Computing. 2010;48(5):407-413.
  90. Petelenz TJ, Buttke JA, Bonds C, Lloyd LB, Beck JE, Stephen RL, Rodriguez P. Iontophoresis of dexamethasone: laboratory studies. Journal of Controlled Release. 1992;20(1):55-66. https://doi.org/10.1016/0168-3659(92)90139-I
  91. Rebersek M, Miklavcic D. Advantages and disadvantages of different concepts of electroporation pulse generation. Automatika. 2011;52(1):12-19. https://doi.org/10.1080/00051144.2011.11828399
  92. Sale AJH, Hamilton WA. Effects of high electric fields on microorganisms: I. Killing of bacteria and yeasts. Biochimica et Biophysica Acta (BBA)-General Subjects. 1967;148(3):781-788.
  93. Potter H. Electroporation in biology: methods, applications, and instrumentation. Analytical Biochemistry. 1998;174(2):361-373.
  94. Flisar K, Puc M, Kotnik T, Miklavcic D. Cell membrane electropermeabilization with arbitrary pulse waveforms. IEEE Engineering in Medicine and Biology Magazine. 2003;22(1):77-81.
  95. De Vuyst E, De Bock M, Decrock E, Van Moorhem M, Naus C, Mabilde C, Leybaert L. In situ bipolar electroporation for localized cell loading with reporter dyes and investigating gap junctional coupling. Biophysical Journal. 2008;94(2):469-479. https://doi.org/10.1529%2Fbiophysj.107.109470
  96. Sanders JM, Kuthi A, Wu YH, Vernier PT, Gundersen MA. A linear, single-stage, nanosecond pulse generator for delivering intense electric fields to biological loads. IEEE Transactions on Dielectrics and Electrical Insulation. 2009;16(4):1048-1054. https://doi.org/10.1109/TDEI.2011.5976120
  97. Nuccitelli R, Pliquett U, Chen X, Ford W, Swanson RJ, Beebe SJ, Schoenbach KH. Nanosecond pulsed electric fields cause melanomas to self-destruct. Biochemical and Biophysical Research Communications. 2006;343(2):351-360. https://doi.org/10.1016%2Fj.bbrc.2006.02.181
  98. Blumlein AD. Improvements in or relating to apparatus for generating electrical impulses. GB Patent. 1947;589:127.
  99. DeAngelis A, Kolb JF, Zeni L, et al. Kilovolt Blumlein pulse generator with variable pulse duration and polarity. Review of Scientific Instruments. 2008;79(4):1-4.
  100. Kanduser M, Miklavcic D. Electroporation in biological cell and tissue: an overview, Electrotechnologies for Extraction from Food Plants and Biomaterials. Springer Science. 2008;1:37.
  101. Puc M, Flisar K, Rebersek S, Miklavcic D. Electroporator for in vitro cell permeabilization. Radiology and Oncology. 2001;3:5.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.